Omnicell's autonomous pharmacy push and SaaS growth show promise, but rising costs and weak hospital spending cloud its near-term outlook.

Revenue for Omnicell in its third quarter amounted to $311 million, notching the company a 10% gain in the key line item. Going in the opposite direction was net income not according to generally ...

In the preceding three months, 7 analysts have released ratings for Omnicell (NASDAQ:OMCL), presenting a wide array of perspectives from bullish to bearish. The table below offers a condensed view of ...

Omnicell, Inc. OMCL is gaining from robust demand for its medication management and adherence automation solutions. Omnicell is well on track to achieve its 2025 targets, driven by several factors ...

Omnicell , Inc. (NASDAQ:OMCL), a leading provider of medication management solutions in the healthcare technology sector, has been navigating a complex market environment characterized by both ...

Over the past six months, Omnicell has been a great trade, beating the S&P 500 by 19.8%. Its stock price has climbed to $41.48, representing a healthy 26.4% increase. This performance may have ...

Conestoga Capital Advisors, an asset management company, released its “Small Cap Growth Fund” third-quarter investor letter. A copy of the same can be downloaded here. The fund declined 4.56% net of ...